CliniNote’s Post

🌟 Advancing Diagnostic Accessibility: Insights from Industry Leaders 🌟 We are thrilled to share key insights from our recent webinar, "NextGen Diagnostics: Democratizing Access to Advanced Screening," held on June 19, 2024. This engaging session brought together industry experts to explore how cutting-edge technologies can be made accessible to anyone anywhere. Key Insights: 🔹 Daniel Kraft, MD discussed the integration of AI and advanced imaging into diagnostics, emphasizing the need for evolving healthcare models to fully harness these technologies for patient benefit. 🔹 Vin Gupta, MD MPA highlighted the challenges in lung cancer screening, stressing the importance of patient trust and understanding in increasing screening rates. 🔹 Ashkan Afshin, MD ScD, our CEO, shared how proteomics is transforming early disease detection, making it more accessible and cost-effective. 🎙 Moderator: Blandine Merino, AVP of Strategy at Agilent Technologies and founder of Bio2Market, led the discussion with profound insights from her extensive experience in the biotech sector. 🌍 This event underscored the necessity for collaborative efforts among technologists, policymakers, and healthcare providers to ensure new diagnostic tools reach everyone, especially those in greatest need. 👉 Together, let's ensure early disease detection is a right, not a privilege. 👨⚕️ 👩⚕️ For Practicing Physicians: If you are interested in learning more about our upcoming webinars and the next frontiers of diagnostics, please contact us at info@novelna.com. We look forward to engaging with you to advance diagnostic practices globally. 🔗 For more details on Novelna's mission and upcoming events, visit our website at www.novelna.com. 🔗 Learn more about the event at: https://lnkd.in/gMrWvMZg #Novelna #Diagnostics #Proteomics #Cancer #PublicHealth National Cancer Institute (NCI) American Cancer Society Cancer Research UK Science and Innovation Cancer Research Institute (CRI) World Cancer Research Fund NextMed Health Amazon

Today, our team is participating in a capacity building activity within the #EU4Health project CAN.HEAL at the Centre for Research & Technology Hellas (CERTH), in Thessaloniki, Greece. This event focuses on enhancing capacities within the European health sector, particularly in the realm of #cancer treatment and diagnostics through innovative genomic strategies. Our experts, including Els Van Valckenborgh, Brigitte Maes, Nancy Frédérickx, and myself, will present our latest work on the following cutting-edge topics: •  #NGS (Next Generation Sequencing) Implementation in Belgium: A deep dive into the roadmap for NGS in Belgium, covering the ComPerMed initiative, NGS convention, and reimbursement strategies. •  Belgian Precision Approach: Outlining the concept, objectives, and challenges of #precisionmedicine in Belgium. •  #Oncology Decision Support Tool: Introduction of the EU-oncDST concept, aiming to revolutionize oncology decision-making. •  Cancer Diagnostics and Treatment: Discussion on the shared-risk clinical trial (DRUP) and its impact on cancer treatment. •  #Genomics in Public Health: Exploring the 'Genome of Europe' initiative and the Genomic Data Infrastructure (GDI). ℹ Learn more about the CAN.HEAL project here: https://canheal.eu/

#Restlesslearners #Healthcareconsultant 📣 Excited to share insights on the Impact of Molecular Tumor Board (TMB) on Cancer Patient Management! After participating in the first MTB in Colombia and transferring that knowledge to Australia, I experienced the impact of TMB on Cancer Patient Management. This impact goes beyond the proportion of patients who were recommended a change in clinical management and the treating oncologists' compliance with MTB recommendations. I am proud of the work and to have worked with Dr. Frank Lin, a Medical Oncologist and Physician-Data scientist who is developing open-source algorithms for precision oncology. Dr. Lin's tools, such as Therapy-Oriented Precision Oncology Guidelines and Precision Oncology Treatment and Trial Recommender, were used in the Molecular Screening and Therapeutic (MoST) program, offering valuable insights for oncologists in Australia and New Zealand. His legacy is shaping the future of Precision Oncology. Explore Dr. Frank Lin's resources: - Therapy-Oriented Precision Oncology Guidelines: [Link](https://lnkd.in/g7zDtqz6) - Precision Oncology Treatment and Trial Recommender (POTTR): [Link](https://lnkd.in/gDKGtU-H) DISCLAIMER: FOR RESEARCH USE ONLY. Material provided "as is," using TOPOGRAPH comes without warranties, not a substitute for clinical judgment or professional oncology advice. Misuse may cause harm. Exciting news! Dr. Frank Lin will present an update on his work at the American Society of Clinical Oncology (ASCO) 2024. Stay tuned for more updates! 🌟 #PrecisionOncology #CancerCare #MedicalInnovation

📣 𝑻𝒉𝒆 𝒇𝒊𝒓𝒔𝒕 𝑨𝒏𝒏𝒖𝒂𝒍 𝑴𝒆𝒆𝒕𝒊𝒏𝒈 𝒐𝒇 𝒕𝒉𝒆 “𝑷𝒓𝒆𝒗𝒆𝒏𝒕𝒊𝒐𝒏, 𝒊𝒏𝒄𝒍𝒖𝒅𝒊𝒏𝒈 𝒔𝒄𝒓𝒆𝒆𝒏𝒊𝒏𝒈” 𝑪𝒍𝒖𝒔𝒕𝒆𝒓 𝒐𝒇 𝒑𝒓𝒐𝒋𝒆𝒄𝒕𝒔 𝒘𝒊𝒍𝒍 𝒃𝒆 𝒉𝒆𝒍𝒅 𝒐𝒏 𝑺𝒆𝒑𝒕𝒆𝒎𝒃𝒆𝒓 7𝒕𝒉 𝒊𝒏 𝑺𝒂𝒏 𝑺𝒆𝒃𝒂𝒔𝒕𝒊𝒂𝒏, 𝑺𝒑𝒂𝒊𝒏. 📣 In the late 2022, in response to the Horizon Europe call titled ”Develop new methods and technologies for cancer screening and early detection”, 12 research projects were selected for a total funding of €125.6 million budget to support the EU Mission on Cancer. 𝟳 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀 𝗵𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗶𝗻 𝗮 𝗖𝗹𝘂𝘀𝘁𝗲𝗿 𝗼𝗳 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀 𝗼𝗿𝗶𝗲𝗻𝘁𝗲𝗱 𝗼𝗻 “𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 ”: LUCIA – Understanding Lung Cancer related risk factors and their Impact. MAMMOSCREEN – Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate, inclusive and female-friendly. ONCOSCREEN – A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways. PANCAID – PANcreatic CAncer Initial Detection via liquid biopsy SANGUINE – Early detection and screening of haematological malignancies THERMOBREAST – An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring. DIOPTRA – Early dynamic screening for colorectal cancer via novel protein biomarkers reflecting biological initiation mechanisms. The cluster was built with the scope of supporting the Mission objectives, creating added value and increasing the impact of EU funding The cluster work will be harmonised with the involvement of different joint activities, starting from the draw up of a common work plan for scientific collaborations, which has already been submitted to the EC #mammoscreen #eumissioncancer #prevention #breastcancerprevention #screening #improvinghealth #preventioncluster

"I'd like to leave a permanent dent in a big problem" -Professor David Thomas, CEO of Omico. Professor David Thomas, CEO of Omico, and Associate Professor Craig Underhill, medical oncologist in Albury-Wodonga, joined Health Industry Hub to engage in a comprehensive discussion on Australia’s largest #cancer #genomics program, PrOSPeCT, and the mission of enhanced cancer outcomes. Professor Thomas elaborated on the vision of PrOSPeCT, highlighting the unique funding model born out of public-private partnerships. "The fantastic thing about PrOSPeCT is it's working in that networked way, bringing regional sites into the fold," -A/Professor Underhill. A/Professor Underhill underscored the crucial role of PrOSPeCT in addressing disparities in cancer outcomes between urban and regional Victoria, aligning with his passion for driving equitable access to healthcare. He shared first-hand insights into the challenges facing underserved communities in cancer care and tangible benefits of participating in PrOSPeCT. Professor Thomas outlined key milestones for PrOSPeCT in the short-term, signalling an ongoing commitment to driving enhanced outcomes in cancer care and oncology research. In reimagining healthcare across the entire patient journey, Health Industry Hub is the only one-stop-hub bringing the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change. Visit us at https://lnkd.in/gdMQWkey #oncology #omico #health #healthcare

Pioneering Therapeutic Innovation: Highlights from the First hashtag #THRPTX Summit in Paris-Saclay After months of preparation, we're thrilled to reflect on this groundbreaking symposium that brought together today over 200 international experts, decision-makers, and healthcare professionals at our R&D Institute in Paris-Saclay. 🌍 Global Collaboration: THRPTX united brilliant minds from across the globe, fostering dialogue and collaboration that transcends borders in the pursuit of therapeutic innovation. 🧬 Scientific Excellence: Under the patronage of Nobel Laureate Prof. William G. Kaelin Jr., we explored cutting-edge innovations in oncology, from diagnosis to post-cancer care, and the profound impact of medical advancements on society. 🤝 Cross-disciplinary Synergy: The summit exemplified the power of cross-functionality, leveraging the Paris-Saclay ecosystem to accelerate R&D effectiveness and drive forward-thinking solutions in healthcare. 🔬 Patient-Centric Innovation: Discussions centered on patient needs, highlighting our commitment to developing therapies that positively impact patients' lives and their families. 💡 Future-Focused Dialogue: From AI and digital tools to the role of health data, we delved into the future of medical practices and society's expectations for health innovation. A special moment was the engaging exchange between Prof. Kaelin and Selena Bouffette, a Servier doctoral student representing our SHINEDocs community – bridging generations of scientific talent. Heartfelt thanks to Olivier Laureau, Claude Bertrand, and all the speakers, participants, and organizers who made THRPTX a resounding success. This summit reaffirms our position as a key player in global health innovation. As we look ahead, we're excited to continue driving therapeutic breakthroughs that will shape the future of healthcare and science. #TherapeuticInnovation #oncology #AI #MovedByYou #WeAreServier

I think that anyone who has heard Omico's David Thomas speak about accelerating access to precision oncology for Australians knows that he has already made a dent in this big problem and has a relentless focus to make this standard of care for Australians. Our Omico team and all our incredible partners across Australia are working hard towards this. Bigger dent coming!!! 👉 If you or someone you love has advanced, incurable or a poor prognosis cancer, don't forget that they could ask their oncologist to help them access the free comprehensive genomic profiling that Omico is providing via our PrOSPeCT initiative. More information about a patient's cancer can help to to identify potential targeted therapies that could improve outcomes. www.omico.org.au Thanks Health Industry Hub & Rozalina Sarkezians for highlighting this important initiative and the opportunity for patients, medical oncologists, industry and government to improve cancer outcomes. #CancerMeetsItsMatch #PrecisionOncology

In this interview, Omico's founder David Thomas notes that... "We have moved from a model in cancer where we start with surgery and anatomy, to a molecular, scientific concept of cancer, which is proving to be numerically 6 times as effective in terms of bringing drugs that are likely to work to cancer patients. The science is unquestionable – the question is how do we bring that into our patients’ lives." 👉 6️⃣ TIMES!!! PrOSPeCT provides a way to do this, right now, for Aussies living with advanced, incurable or poor prognosis cancers, by providing comprehensive genomic profiling at no cost to 23,000 Australians. We don't want a single one of these 23,000 opportunities to be missed to bring more information about a patient's cancer that could drive to better treatment options. Let's keep the patient referrals coming from the medical oncology community! The precision oncology trials in Australia are increasing, building access to targeted treatment options. www.omico.com.au #CancerMeetsItsMatch #PrecisionOncology Health Industry Hub Rozalina Sarkezians

The Cancer Profiling Global Market Report 2024 by The Business Research Company reveals promising growth prospects for the cancer profiling market in the coming years. With the market size reaching $13.4 billion in 2024 and projected to soar to $20.35 billion by 2028, this industry is on a trajectory of remarkable expansion. Factors driving this growth include the rising incidence of cancer, the adoption of precision medicine, and advancements in biomarker technologies. Noteworthy trends shaping the landscape include the dominance of liquid biopsy, comprehensive genomic profiling, and the rise of immunoprofiling techniques. Furthermore, technological innovations such as Roche’s AVENIO Edge System and Illumina’s GRAIL acquisition underscore the market's quest for precision and early detection. Segmented by technology, biomarker type, cancer type, and application, this market offers diverse opportunities for stakeholders. As North America emerges as a key player in this arena, collaboration and innovation will continue to be the driving forces behind progress. Stay tuned for updates as we navigate the exciting journey toward personalized cancer care! 🌟 Read More : https://lnkd.in/gk84fmAy #CancerProfiling #MarketInsights #PrecisionMedicine #HealthcareInnovation